News

Qilu Pharmaceutical Awarded as the Best R&D Pipeline Pharmaceutical Company

ABOUT US

News

Qilu Pharmaceutical Awarded as the Best R&D Pipeline Pharmaceutical Company

Release time：

2021-08-02

Qilu Pharmaceutical was awarded as The Best R&D Pipeline Pharmaceutical Company in the 38^th Pharmaceutical Industry Information Annual Conference.

To date, Qilu has launched 300+ products with 47 products “first to launch or exclusive launch in China. Qilu has currently 60 innovative projects in the pipeline, and among them, 10+ innovative projects are in clinical stage and one innovative product will be launched in 2022.

With drugs exported to more than 80 countries and regions, Qilu Pharmaceutical marks the only domestic pharmaceutical company that exports FDF to all the main regulated markets, covering Europe, USA, UK, Japan and Australia, among which 18 of our products enjoy the largest market share. In addition, Qilu Pharmaceutical acts as the pioneer in the exportation of injectable products with commercial package to Japan. To date, 16 FDFs have been marketed in the USA and 10 in Europe. 12 APIs for human use from Qilu Pharmaceutical enjoy the world’s largest market share, including the families of Cephalosporin and Tazobactam.

The Most Socially Responsible Enterprises (Entrepreneurs) in 2021

Qilu Pharmaceutical Ranked No. 9 among Top 100 Chinese Pharmaceutical Companies

Related News

Qilu Pharmaceutical ranks No.3 in the list of "Top 100 Enterprises in Chinese Pharmaceutical industry”

2024-09-30

Qilu Launches First Generic Version of Invega Sustenna® (Paliperidone Palmitate Suspension for Injection) in China

2023-10-12

Qilu Pharmaceutical launched the first innovative drug in China

2023-09-01

Qilu Pharmaceutical Group Awarded as Socially Responsible Enterprises (Entrepreneurs) in 2022

2023-04-04

Qilu Pharmaceutical ranks No.5 in the list of "Top 100 Enterprises in Chinese Pharmaceutical Industry”